We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




POC Diagnostic Platform Combines Immunoassay and Molecular Testing

By LabMedica International staff writers
Posted on 14 May 2025

An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design. More...

This platform not only demonstrates true lab-quality sensitivity, even with the most challenging clinical samples, but also maintains low invalid rates and minimal system downtime.

Cubit Diagnostics (Carlsbad, CA, USA) is further advancing the development of its integrated immunoassay and molecular benchtop analyzer, specifically designed for use in doctor’s offices and pharmacies, eliminating the need for multiple platforms and complicated testing workflows. The Cubit platform leverages a proprietary purification method and affordable microfluidic technologies to provide actionable results exactly when and where they are needed. By integrating cutting-edge target extraction technology with a simple, cost-effective design, CubitDx is addressing long-standing challenges in diagnostics. The result is laboratory-grade performance without sacrificing affordability, supporting the increasing trend of digital health and enabling more accessible care. The platform can simultaneously test up to 8 targets per run, offering comprehensive syndromic testing while performing both immunoassays and molecular testing on a single platform.

While initially focused on COVID-19, Flu A, and Flu B, the CubitDx platform is designed to tackle a wide range of critical health issues, including sepsis, sexually transmitted diseases (STDs), HIV, and HPV in the future. Evaluation results show that the CubitDx platform’s COVID-19 assay provides higher sensitivity than standard rapid tests and matches the sensitivity of large, high-throughput clinical laboratory systems. With the ability to deliver lab-quality results in just 15 minutes at the point of care, the platform aims to bring high-performance diagnostics closer to patients, improving both outcomes and accessibility worldwide. Offering affordable, high-sensitivity diagnostics for both resource-rich and cost-sensitive markets, the CubitDx platform has the potential to revolutionize healthcare access globally, from U.S. hospitals to underserved communities across Asia and Africa.

Related Links:
Cubit Diagnostics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Droplet Digital PCR System
QX600 AutoDG
New
STI Test
REALQUALITY RQ-SevenSTI
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.